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Copyright © 2008 JCBN Heme oxygenase (HO) exists as constitutive (HO-2, HO-3) and inducible isoforms (HO-1), the latter which
responds to regulation by multiple stress-stimuli [1]. Several signaling molecules (e.g., mitogen-activated protein
kinases), transcriptional regulators (activator protein-1, NF-E2-related factor-2, hypoxia-inducible factor-1, Bach-1),
as well as two enhancer regions in the ho-1 5' regulatory region, participate in the regulation of the ho-1 gene [2].
Recent progress indicates that carbon monoxide (CO), a gaseous second messenger, exerts novel anti-inflammatory
and anti-apoptotic effects (Table 1), although little is known about the precise molecular mechanism of these actions.
There has been many reports that inhalation of CO could be protective against acute ischemia-reperfusion injury in
intestine, lung, kidney, and liver (Table 2). More recent report indicates that inhalation of 100–125 ppm CO by
patients with chronic obstructive pulmonary disease is feasible and leads to trends in reduction of sputum eosinophils
and improvement of responsiveness to methacholine [3]. In addition to beneficial effects of CO, further studies need
to confirm the safety of this gas, especially in the cardiac function [4, 5]. In this serial review, we invited several
outstanding researchers in this field to summarize their work, to review their peers’ activity, and to encourage us their
opinions. I thank all the anonymous reviewers of these articles for their insightful comments.
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Table 1. Mechanisms of anti-inflammatory and cytoprotective
effects of carbon monoxide
Inhibition of chemokines and chemokine receptors
Inhibtion of ICAM-1
Inhibition of iNOS expression and NO production
Inhibition of Th1 type cytokines (IL-2, IFNγ)
Inhibition of proinflammatory mediators (IL-1β, TNFα, 
IL-6, COX-2)
Augmentation of IL-10
Heme oxygenase-1-dependent pathway
Nuclear factor-κB-independent pathway
Soluble guanylyl cyclase (sGC)-dependent pathway
p38MAPK pathway-dependent
Akt-eNOS pathway-dependentHO-1/CO system in biology and medicine
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Table 2. Effects of inhalated carbon monoxide on experimental disease models in rodents
Animal Organ Model
Carbon monoxide
Efficacy Year Authors
Conc. Duration
Rat Lung Hyperoxic injury 250 ppm 56 h Effective 1999 Otterbein et al.
Mouse Lung Inflammation by aeroallergen 250 ppm 48 h Effective 2001 Chapman et al.
Rat Lung Hyperoxic lung injury 50–500 ppm 60 h No change 2001 Clayton et al.
Rat Intestine Ischemia/Reperfusion 250 ppm 1 h Effective 2003 Nakao et al.
Rat Intestine Graft motility 250 ppm 25 h Effective 2003 Nakao et al.
Mouse Intestine Postoperative ileus 250 ppm 24 h Effective 2003 Moore et al.
Mouse Lung Airway Hyperesponsiveness 250 ppm 1 h/day, 5 day Effective 2003 Ameredes et al.
Rat Heart Ischemia/Reperfusion 1000 ppm 30 min Effective 2004 Fujimoto et al.
Rat Kidney Ischemia/Reperfusion 250 ppm 25 h Effective 2004 Neto et al.
Mouse Lung Acute injury, ARDS 500 ppm 1 h No change 2005 Ghosh et al.
Rat Liver Ischemia/Reperfusion 100 ppm 25 h Effective 2005 Kaizu et al.
Rat Intestine Necrotizing enterocolitis 250 ppm 1h/day, 3day Effective 2005 Zuckerbraun et al.
Mouse Multiple organ Hemorrhagic shock 250 ppm 1 h Effective 2005 Zuckerbraun et al.
Rat Intestine Postoperative ileus 250 ppm 24 h Effective 2005 Moore et al.
Mouse Intestine IL-10-deficient colitis 250 ppm 24 h Effective 2005 Hegazi et al.
Rat Heart Myocardial infarction 500 ppm 3 week Worse 2005 Mirza et al.
Mouse Liver Ischemia/Reperfusion 250 ppm 1 h Effective 2005 Ott et al.
Pig Lung Endotoxin shock 250 ppm 1 h Effective 2005 Mazzola et al.
Rat Heart Allograft survival 20 ppm 14–100 days Effective 2006 Nakao et al.
Rat Kidney Allograft nephrophathy 20 ppm 30 days Effective 2006 Neto et al.
Rat Lung Donors/recipients 250 ppm pre (1 h)/after Effective 2006 Kohmoto et al.
Rat Heart Dysfunction/hypoxia 100 ppm 90 min Worse 2006 Favory et al.
Swine Vein Intinal hyperplasia 100/250 ppm pre/intraope. Effective 2007 Ramlawi et al.
Mouse Liver Fulminant hepatitis 250 ppm 1 h Effective 2007 Tsui et al.
Rat Heart Dysfunction/hypoxia 50 pm 1 week Worse 2007 Gautier et al.
Rat Lung Ischemia/Reperfusion 250 ppm 2 h Effective 2007 Boutros et al.
Rat Multiple organ LPS-induced MOF 250 ppm 3 h Effective 2007 Liu et al.
Rat Liver Transplantation 20–250 ppm pre (1 h)/after (24 h) Effective 2007 Kaizu et al.